Figure 2 | Leukemia

Figure 2

From: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Figure 2

Quantitative phosphoproteomic analysis of mutant JAK3 L857Q Ba/F3 cells. (a) Venn diagram summary of results from experimental workflow after mapping of all phospho-proteomic data across all experiments. (b and c) Distribution of quantitative phosphorylation changes of tofacitinib/control and ruxolitinib/control. (d and e) Tofacitinb (500 nM) treatment resulted in 84 down- and 29 upregulated phosphorylation sites (significance reported for changes versus control of ±0.5 log2 fold). (e) Ruxolitinib (500 nM) treatment resulted in 86 down- and 20 upregulated phosphorylation sites (significance reported for changes versus control of ±0.5 log2 fold). (f) STAT5A showed consistent downregulation across all three replicates upon tofacitinib and ruxolitinib treatment in the phospho-proteomic screen. (g) Western blot analysis further validated the decrease in phospho-STAT5 (Y694) upon treatment with JAK selective inhibitors tofacitinib and ruxolitinib.

Back to article page